{
  "docId": "019de073-187a-71e9-a3c0-2f4159454068",
  "docSlug": "48ce63a07f3c546c39a71c96ea43409e",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 40,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "Includes clinical trial data (KM curves, hazard ratios, median OS) and strategic updates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-187a-71e9-a3c0-2f4159454068/15",
  "deckHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068",
  "deckJsonHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068.json",
  "deckAnchorHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.38,
        "y": 0.35
      },
      "kind": "chart",
      "text": "capivasertib Phase II FAKTION KM curve",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70e985bb-9531-43ac-a87d-cf8b5b0673f6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.04,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Enhertu Phase III DESTINY-Breast04 KM curve",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92aee3d3-6c6c-4104-9829-c36a831edadb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "disclaimer",
      "text": "ASCO = American Society of Clinical Oncology; HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry; CDK4/6i = cyclin-dependent kinases 4 and 6 inhibitors; HR+/HER2- = hormone receptor positive; human epidermal growth factor receptor 2 negative; PI3K = phosphatidylinositol-3 kinase; AKT = protein kinase B; PTEN = phosphatase and TENsin homolog; OS = overall survival; CD19 = cluster of differentiation 19; CD3 = cluster of differentiation 3. Enhertu developed in collaboration with Daiichi Sankyo.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14d9dd2c-f687-41c6-8eb2-18eecb275e11",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.68,
        "y": 0.35
      },
      "kind": "image",
      "text": "TNB-486 antibody structure diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b7a1915-e52b-4dbd-94f5-20204c3fc637",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.28,
        "x": 0.04,
        "y": 0.63
      },
      "kind": "list",
      "text": "Enhertu highlights",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19016340-fcde-4bbe-9d76-82b263cd5f6f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.35,
        "y": 0.63
      },
      "kind": "list",
      "text": "capivasertib highlights",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5b01a32c-b639-4f61-9b9d-a94bf6f0f29d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.67,
        "y": 0.63
      },
      "kind": "list",
      "text": "TNB-486 highlights",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "857ade16-9e22-4e44-aff2-daf92440541c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Exceptional data at ASCO, new T-cell engager for haematology",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e64c3e5-bd56-44a0-b39f-134c81f1b7c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Oncology: Q2 2022 R&D highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "262b48d9-c9ef-42b9-a231-2e394ddc7293",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "eb0e6dd4-f041-4d47-87f5-26e8bc499164",
      "evidence": "list/bullet: capivasertib highlights",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}